AIBODY: From world's first digital human organism to every patient's digital twin
AIBODY is the world’s first physiology-as-a-service platform that realistically replicates all biophysical, physiological, and biochemical processes occurring within a human body and responds to any simulated medical condition or treatment virtually, in the way that a real human organism would. AIBODY’s digital patient software is the culmination of more than two decades of efforts by a world-class team of medically trained experts who have successfully recreated a human being in computer code, incorporating everything we know about biochemistry and physiology from the sub-cellular level up. AIBODY’s first cloud-based digital human organism, named Luke, was introduced to the public in 2021.
The story of AIBODY, and of Luke, begins in Vinnytsia, a mid-sized city in Ukraine, in the years following the collapse of the Soviet Union. A small group of talented medical professionals who also had a passion for computer science began experimenting with bringing those two worlds together, laying the foundation for a digital human organism. Alex Ousach, a high-tech entrepreneur born in Vinnytsia, saw the enormous potential that this technology could have for global healthcare and decided to fund it. Alex took this project under the umbrella of AUG Global, his international technology consulting group, built up the team and supported their R&D efforts for over 20 years. In 2021, AIBODY was spun out as a separate entity, headquartered in London and led by a group of UK-based executives dedicated to commercializing this ground-breaking technology.
Early on, the AIBODY team recognized the limitations of existing attempts to model human physiology and chose to take a different, more complex approach. Rather than using linear equations to mimic aspects of human physiology from the top down, the team worked from the sub-cellular level up, creating AIBODY’s digital biochemistry by utilizing computer code to describe chemical elements and their interactions with each other within a cell. The process of modelling biochemistry and all intra-cellular transformations is exceptionally complex, and it took over six years to build the first digital cell as well as a module that allowed configuration of any human cell type by calibrating a number of specific cellular attributes.
After reaching this important milestone, the AIBODY team was able to model how cells communicate with each other by transfer of electrical impulses (for heart or nerve tissue) and by hormonal signaling through the cell surface receptors. That, in turn, enabled AIBODY to progress further by using digital cells to build tissue and organs and form organ systems. Finally, AIBODY developed models to govern all processes and transformations of various parts of the human body, bringing everything together and creating a true-to-life, digital human organism. The initial stage of this journey was over, and Luke was born.
Based on this unique approach to the scientific development of AIBODY, its software is now the world’s most effective physiological and medical simulation engine. Put simply, this technology replicates the complete human physiology from the sub-cellular level up, ensuring that Luke (the digital patient) responds to injury, disease, and medical treatment just as a real, human patient would.
After the two decades of continuous development in Ukraine, AIBODY launched its Digital Human Organism at MEDICA 2021, the world’s largest medical trade fair, where we were supported by Medilink UK. We received positive feedback and a warm reception from the healthcare community. AIBODY subsequently participated in other major trade shows, including ITSEC in Orlando, IMSH in Los Angeles, and Arab Health in Dubai, generating interest from a wide range of medical training/education and healthcare provider organizations from the United States and Asia. As a result, we are now considering a broad range of applications, including medical education, medical certification training, battlefield trauma training, medical device development, and uses in clinical decision support.
We attribute the broad interest in our technology not just to the advantages offered by our unique digital patient platform, but also to the growing interest in digital and cloud-based healthcare solutions overall. The global pandemic has accelerated the structural changes which were already underway in medical education by sharply increasing the demand for remote learning and training resources that can be easily available and accessible from anywhere at any time. In addition, the healthcare community is now demanding more sophisticated and realistic digital training tools, creating increased demand for more interactive and practical online content as well as highly immersive, AR and VR-based training solutions designed to facilitate practical experiences for students in a safe learning environment. Haptic feedback technologies (HaptX, VRGluv, Manus) are beginning to play a role in this field, and as the technology matures, their role will increase in importance and greatly enhance training experiences. Finally, we are also seeing efforts by forward-thinking high-fidelity manikin providers to incorporate sophisticated physiology into their products to expand their capabilities and equip them to meet the needs of the next generation of medical students and trainees.
A glimpse into the future
To maximize benefits to patients worldwide through support of medical education and clinical practice, AIBODY envisions moving “beyond Luke” into digital twinning – the creation of a digital representation of a particular patient’s condition or the patient themselves. For AIBODY specifically, the concept of digital twinning means the creation of a digital patient with a physiology calibrated to represent the actual physiology of a specific real-world patient, be they healthy or otherwise. Eventually, we envision a doctor opening AIBODY’s app to see the digital physiology of a patient before even seeing them in person and using the platform to power new clinical decision support systems for improved diagnosis, therapy and prognosis of multiple conditions. Ultimately, this will facilitate hyper-personalized medicine, in which clinical decisions will be made based on fully contextualized data.
Furthermore, leveraging AIBODY’s unique technology and digital twinning, we can develop personal health apps for the general population to help regular people manage their health collaboratively with their doctors via interaction with their own digital twin.
We are proud of our Ukrainian colleagues who spent 20 years successfully building a technology which can soon bring positive impact to millions of people globally. Our goal is simple – to improve patient outcomes. AIBODY will achieve this by leveraging its technology to unlock the next stage of development for medical education solutions and clinical practice tools.